User login
Key clinical point: Preliminary results from this real-world study demonstrated efficacy of interleukin (IL)-23 inhibitors in patients with psoriatic arthritis (PsA).
Major finding: A substantial proportion of patients with PsA receiving either of the IL-23 inhibitors achieved complete (40.9%) or partial (36.4%) remission compared with only 18.2% of patients who demonstrated no improvement. A higher proportion of patients receiving guselkumab achieved remission or partial remission (38.5% and 46.1%, respectively) than treatment failure (15.4%), with similar outcomes being observed with risankizumab.
Study details: Findings are from a retrospective, observational study including 80 patients with psoriasis who received guselkumab, tildrakizumab, or risankizumab, of which 27.5% of patients had PsA.
Disclosures: This study did not receive any funding. The authors declared serving as consultants, paid speakers, and/or advisors and/or receiving speaking fees or grants from several sources.
Source: Elgaard CDB et al. Guselkumab, tildrakizumab and risankizumab in real-world setting: Drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2022;1-24 (Oct 6). Doi: 10.1080/09546634.2022.2133531.
Key clinical point: Preliminary results from this real-world study demonstrated efficacy of interleukin (IL)-23 inhibitors in patients with psoriatic arthritis (PsA).
Major finding: A substantial proportion of patients with PsA receiving either of the IL-23 inhibitors achieved complete (40.9%) or partial (36.4%) remission compared with only 18.2% of patients who demonstrated no improvement. A higher proportion of patients receiving guselkumab achieved remission or partial remission (38.5% and 46.1%, respectively) than treatment failure (15.4%), with similar outcomes being observed with risankizumab.
Study details: Findings are from a retrospective, observational study including 80 patients with psoriasis who received guselkumab, tildrakizumab, or risankizumab, of which 27.5% of patients had PsA.
Disclosures: This study did not receive any funding. The authors declared serving as consultants, paid speakers, and/or advisors and/or receiving speaking fees or grants from several sources.
Source: Elgaard CDB et al. Guselkumab, tildrakizumab and risankizumab in real-world setting: Drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2022;1-24 (Oct 6). Doi: 10.1080/09546634.2022.2133531.
Key clinical point: Preliminary results from this real-world study demonstrated efficacy of interleukin (IL)-23 inhibitors in patients with psoriatic arthritis (PsA).
Major finding: A substantial proportion of patients with PsA receiving either of the IL-23 inhibitors achieved complete (40.9%) or partial (36.4%) remission compared with only 18.2% of patients who demonstrated no improvement. A higher proportion of patients receiving guselkumab achieved remission or partial remission (38.5% and 46.1%, respectively) than treatment failure (15.4%), with similar outcomes being observed with risankizumab.
Study details: Findings are from a retrospective, observational study including 80 patients with psoriasis who received guselkumab, tildrakizumab, or risankizumab, of which 27.5% of patients had PsA.
Disclosures: This study did not receive any funding. The authors declared serving as consultants, paid speakers, and/or advisors and/or receiving speaking fees or grants from several sources.
Source: Elgaard CDB et al. Guselkumab, tildrakizumab and risankizumab in real-world setting: Drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2022;1-24 (Oct 6). Doi: 10.1080/09546634.2022.2133531.